Immunovant Current Assets

Immunovant (IMVT) currently reports a current assets of $850M as of June 2026. That compares with $650M in the prior-year period — up 30.6% year over year. Use the charts on this page to explore Immunovant's current assets history and peer comparisons.

Immunovant's current assets increased from $650M to $850M — a 30.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Immunovant reported $850M in current assets as of June 2026. That compares with $650M in the prior-year period — up 30.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current assets of $850M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Immunovant, and consider following IMVT for alerts when major investors trade the stock.

Immunovant is classified in the Healthcare sector. On current assets, it currently shows $850M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMVT with unrelated industries.